EGFR and neoplasm: There could be a few reasons for the discrepancy between the solid and liquid biopsy in the two discordant samples—(a) the sensitivity of the cobas platform used to determine the EGFR status in solid tumor biopsies is at 1.4%‐5%, or (b) genetic profiling of fine needle aspirate cytology (FNAC) solid tumor biopsies may miss mutations depending upon the site of biopsy due to tumor heterogeneity.